X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 70.91 CNY -0.69% Market Closed
Market Cap: 28.8B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Income Statement

Earnings Waterfall
Xiamen Amoytop Biotech Co Ltd

Revenue
2.2B CNY
Cost of Revenue
-152m CNY
Gross Profit
2.1B CNY
Operating Expenses
-1.4B CNY
Operating Income
722m CNY
Other Expenses
-121.9m CNY
Net Income
600.1m CNY

Income Statement
Xiamen Amoytop Biotech Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024
Revenue
Revenue
597
N/A
665
+12%
730
+10%
771
+6%
771
0%
762
-1%
794
+4%
822
+4%
904
+10%
1 043
+15%
1 132
+9%
1 262
+11%
1 378
+9%
1 466
+6%
1 527
+4%
1 601
+5%
1 716
+7%
1 843
+7%
2 100
+14%
2 226
+6%
Gross Profit
Cost of Revenue
(75)
(77)
(80)
(87)
(85)
(87)
(84)
(87)
(92)
(103)
(125)
(145)
(161)
(176)
(169)
(179)
(167)
(151)
(140)
(152)
Gross Profit
522
N/A
589
+13%
650
+10%
684
+5%
686
+0%
675
-2%
710
+5%
734
+3%
811
+10%
941
+16%
1 007
+7%
1 116
+11%
1 217
+9%
1 289
+6%
1 358
+5%
1 422
+5%
1 548
+9%
1 692
+9%
1 960
+16%
2 074
+6%
Operating Income
Operating Expenses
(439)
(486)
(531)
(539)
(532)
(527)
(556)
(568)
(620)
(704)
(767)
(838)
(881)
(929)
(959)
(994)
(1 084)
(1 124)
(1 276)
(1 352)
Selling, General & Administrative
(397)
(442)
(486)
(506)
(495)
(494)
(504)
(505)
(552)
(628)
(701)
(772)
(833)
(852)
(843)
(867)
(921)
(952)
(1 064)
(1 127)
Research & Development
(49)
(49)
(49)
(53)
(58)
(59)
(73)
(79)
(82)
(89)
(78)
(85)
(95)
(126)
(146)
(167)
(175)
(192)
(226)
(236)
Depreciation & Amortization
0
(3)
(6)
0
0
0
(6)
0
0
0
(7)
0
0
0
(9)
0
0
0
(11)
0
Other Operating Expenses
7
8
10
19
21
28
27
17
13
13
19
19
46
49
39
40
12
20
25
11
Operating Income
83
N/A
102
+23%
119
+16%
145
+21%
154
+7%
149
-4%
154
+4%
167
+9%
192
+15%
237
+24%
240
+1%
278
+16%
336
+21%
360
+7%
398
+11%
428
+7%
464
+8%
569
+22%
685
+20%
722
+5%
Pre-Tax Income
Interest Income Expense
(5)
(5)
(3)
(2)
(1)
1
4
6
8
9
8
9
8
9
8
9
7
7
9
10
Non-Reccuring Items
0
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(13)
0
Gain/Loss on Disposition of Assets
0
0
0
0
0
0
(1)
0
0
0
(2)
0
0
0
(0)
0
0
0
(1)
0
Total Other Income
(23)
(25)
(25)
(26)
(26)
(24)
(18)
(20)
(25)
(31)
(31)
(41)
(45)
(52)
(51)
(50)
(44)
(39)
(39)
(38)
Pre-Tax Income
56
N/A
73
+31%
91
+25%
116
+28%
127
+9%
126
-1%
139
+11%
153
+10%
175
+14%
214
+23%
215
+0%
246
+14%
299
+22%
317
+6%
356
+12%
387
+9%
428
+10%
537
+25%
641
+19%
694
+8%
Net Income
Tax Provision
(8)
(15)
(27)
(30)
(32)
(27)
(23)
(24)
(32)
(46)
(34)
(41)
(56)
(64)
(69)
(74)
(72)
(81)
(85)
(94)
Income from Continuing Operations
48
58
64
86
95
99
117
129
142
168
181
204
243
254
287
314
356
456
555
600
Net Income (Common)
48
N/A
58
+21%
64
+12%
86
+34%
95
+11%
99
+3%
117
+18%
129
+10%
142
+11%
168
+18%
181
+8%
204
+13%
243
+19%
254
+5%
287
+13%
314
+9%
356
+13%
456
+28%
555
+22%
600
+8%
EPS (Diluted)
0.13
N/A
0.15
+15%
0.18
+20%
0.23
+28%
0.25
+9%
0.25
N/A
0.29
+16%
0.31
+7%
0.34
+10%
0.4
+18%
0.45
+13%
0.5
+11%
0.6
+20%
0.63
+5%
0.71
+13%
0.77
+8%
0.87
+13%
1.12
+29%
1.37
+22%
1.48
+8%

See Also

Discover More